Moreover, the 36-month beta value for PIRS is 0.64. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PIRS is 1.32M and currently, short sellers hold a 0.78% of that float. On August 09, 2024, PIRS’s average trading volume was 119.20K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PIRS) stock’s latest price update
The stock price of Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has dropped by -5.71 compared to previous close of 16.46. Despite this, the company has seen a fall of -9.13% in its stock price over the last five trading days. prnewswire.com reported 2024-07-24 that MILWAUKEE, July 24, 2024 /PRNewswire/ — Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella. Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
PIRS’s Market Performance
Pieris Pharmaceuticals Inc (PIRS) has experienced a -9.13% fall in stock performance for the past week, with a 120.14% rise in the past month, and a 39.32% rise in the past quarter. The volatility ratio for the week is 7.70%, and the volatility levels for the past 30 days are at 11.49% for PIRS. The simple moving average for the past 20 days is 24.87% for PIRS’s stock, with a 15.23% simple moving average for the past 200 days.
Analysts’ Opinion of PIRS
Many brokerage firms have already submitted their reports for PIRS stocks, with Robert W. Baird repeating the rating for PIRS by listing it as a “Outperform.” The predicted price for PIRS in the upcoming period, according to Robert W. Baird is $5 based on the research report published on March 13, 2020 of the previous year 2020.
Robert W. Baird gave a rating of “Outperform” to PIRS, setting the target price at $5 in the report published on May 14th of the previous year.
PIRS Trading at 46.53% from the 50-Day Moving Average
After a stumble in the market that brought PIRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.86% of loss for the given period.
Volatility was left at 11.49%, however, over the last 30 days, the volatility rate increased by 7.70%, as shares surge +137.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +59.18% upper at present.
During the last 5 trading sessions, PIRS fell by -9.13%, which changed the moving average for the period of 200-days by -25.10% in comparison to the 20-day moving average, which settled at $12.88. In addition, Pieris Pharmaceuticals Inc saw 6.59% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for PIRS
Current profitability levels for the company are sitting at:
- -0.5 for the present operating margin
- 0.86 for the gross margin
The net margin for Pieris Pharmaceuticals Inc stands at -0.4. The total capital return value is set at -0.93. Equity return is now at value -86.86, with -29.09 for asset returns.
Currently, EBITDA for the company is -14.06 million with net debt to EBITDA at -1.59. When we switch over and look at the enterprise to sales, we see a ratio of 0.03. The receivables turnover for the company is 5.65for trailing twelve months and the total asset turnover is 1.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.92.
Conclusion
To wrap up, the performance of Pieris Pharmaceuticals Inc (PIRS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.